NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings Dividend

NewAmsterdam Pharma Company N.V. Ordinary Shares’s revenue jumped 2.08% since last year same period to $3.04Mn in the Q1 2026. On a quarterly growth basis, NewAmsterdam Pharma Company N.V. Ordinary Shares has generated 9400% jump in its revenue since last 3-months.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s net profit fell -22.55% since last year same period to $-48.44Mn in the Q1 2026. On a quarterly growth basis, NewAmsterdam Pharma Company N.V. Ordinary Shares has generated 35.35% jump in its net profits since last 3-months.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s net profit margin fell -20.05% since last year same period to -1593.45% in the Q1 2026. On a quarterly growth basis, NewAmsterdam Pharma Company N.V. Ordinary Shares has generated 99.32% jump in its net profit margins since last 3-months.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at -0.47 - a -17.87% fall from last quarter’s estimates.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s earning per share (EPS) estimates for the current year stand at -0.47.

NewAmsterdam Pharma Company N.V. Ordinary Shares’s earning per share (EPS) fell -13.27% since last year same period to -0.34 in the Q1 2026. This indicates that the NewAmsterdam Pharma Company N.V. Ordinary Shares has generated -13.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. NewAmsterdam Pharma Company N.V. Ordinary Shares’s return on assets (ROA) stands at -0.17.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. NewAmsterdam Pharma Company N.V. Ordinary Shares’s return on equity (ROE) stands at -0.29.